Evidence map›Paper›PMID 38722434›Full record

ArticleBiochemical genetics2025

Impact of Doxorubicin and Docetaxel on Immune Checkpoint Expression in Colorectal Cancer: Insights into Chemotherapy Resistance Mechanisms.

Mahya Ahmadpour Youshanlui, Hadi Nasiri, Zahra Valedkarimi, Mohammadreza Sadeghi, Morteza Akbari, Kimia Motlagh Asghari, Fereshteh Jamali, Deniz Abdi, Bahareh Mehramouz, Farnaz Rasi Bonab and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mahya Ahmadpour Youshanlui *Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Hadi Nasiri *Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Zahra ValedkarimiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammadreza SadeghiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Morteza AkbariImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Kimia Motlagh AsghariImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Fereshteh JamaliImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Deniz AbdiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Bahareh MehramouzDepartment of Pathobiology, Tabriz University of Medical Sciences, Tabriz, Iran.
Farnaz Rasi BonabImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Behzad BaradaranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. baradaranb@tbzmed.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After chemotherapy, tumor cells tend to become more aggressive, making it challenging for natural and adaptive immune responses to fight them. This often results in recurrence and metastasis, leading to higher mortality rates. The purpose of this study is to discover the mechanisms that cause chemotherapy resistance, including altered expression of immune checkpoints, in a colorectal cancer cell line. We used conventional methods to culture the SW-1116 colorectal cancer cell line in this study. The MTT assay was used to determine the IC50 and efficacy of Docetaxel and Doxorubicin. After treatment, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to analyze PD-L1, CTLA-4, and VISTA gene expression in the SW-1116 cell line. The upregulation of VISTA expression showed a significant increase (p < 0.0001) in response to both chemotherapy agents. Moreover, the expression of CTLA-4 exhibited a remarkable level of significance (p < 0.0001), and PD-L1 expression also displayed notable significance (p < 0.0001). Chemotherapeutic agents heighten immune checkpoint gene expression, highlighting potential immune response pathway modulation.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsDocetaxelDoxorubicinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticImmune Checkpoint ProteinsB7 AntigensB7-H1 AntigenCell Line, TumorCTLA-4 AntigenHumansAntineoplastic AgentsB7 AntigensB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanDocetaxelDoxorubicinImmune Checkpoint ProteinsVSIR protein, humanChemotherapy resistencyColorectal cancerCTLA-4ImmunecheckpointPD-L1VISTA

Identifiers

PMID38722434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.